Teriparatide biosimilar - Rhein Minapharm BiogeneticsAlternative Names: Modified PTH
Latest Information Update: 05 Feb 2014
At a glance
- Originator Rhein Minapharm Biogenetics
- Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Osteoporosis
Most Recent Events
- 08 Jan 2014 Investigation in Osteoporosis in Egypt (Parenteral)